Supernus Pharmaceuticals Inc.’s (SUPN) share price has entered into oversold territory with an RSI value of 27.1. The Zacks Consensus Estimate on Supernus Pharmaceuticals Inc.’s earnings for the full year period has loss of 0.01 cents over the past two months to $-2.49 per share. Currently, Supernus Pharmaceuticals Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (SUPN) after its recent drop.
SUPERNUS PHARMACEUTICALS INC (SUPN): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry